Lumida
/KNSA
⌘K
Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals International PLC

KNSA
$76.27USD-0.27%-0.21 today

MARKET CAP

6.0B

P/E (TTM)

83.8x

FWD P/E

DAY RANGE

$76 – $79

52W RANGE

$35
$83

AI Summary

Stalk
StalkMedium

The mid-August Momentum Breakout confirms medium-term bullish asymmetry, but the recent pullback below the 9- and 20-day EMAs alongside a declining RSI signals short-term hesitation. Price remains above the rising 50-day SMA and 200-day SMA, preserving the broader uptrend. Execution should be deferred until price shows acceptance near the 50-day SMA, with a reclaim of the 20-day EMA providing renewed entry readiness.

  • Q4 2025 ARCALYST revenue hit $202.1 M (+65% YoY); FY 2025 total $677.6 M (+62%)
  • Raised full-year 2026 net revenue outlook to $900–920 M after robust Q2
  • Valuation risk: weak earnings yield and low book-to-price metrics suggest limited upside
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$38.5M$220.2M$270.3M$423.2M$677.6M
YoY %+471.2%+22.7%+56.6%+60.1%
P / Sales20.9x4.6x4.9x3.3x4.8x
EV / Sales19.0x4.3x4.9x3.2x4.9x
Gross Profit, Adj.$28.6M$173.2M$236.9M$362.3M$599.9M
YoY %+505.5%+36.7%+53.0%+65.6%
Margin %74.2%78.7%87.6%85.6%88.5%
EV / Gross Profit25.6x5.5x5.5x3.8x5.5x
EBITDA, Adj.$-154.3M$12.2M$-22.9M$-43.9M$78.8M
YoY %+0.4%+107.9%-287.7%-92.2%+279.4%
Margin %-400.3%5.5%-8.5%-10.4%11.6%
EV / EBITDA-4.7x78.7x-57.4x-31.2x41.7x
EBIT$-156.6M$9.8M$-25.2M$-45.6M$77.2M
YoY %+0.5%+106.2%-357.8%-81.0%+269.3%
Margin %-406.4%4.4%-9.3%-10.8%11.4%
EV / EBIT-4.7x98.0x-52.1x-30.1x42.6x
Net Income$-157.9M$183.4M$14.1M$-43.2M$59.0M
YoY %+2.1%+216.1%-92.3%-406.7%+236.6%
Net Margin-409.7%83.3%5.2%-10.2%8.7%
EPS (GAAP)-$2.30$2.60$0.20-$0.60$0.75
YoY %+11.9%+213.0%-92.3%-400.0%+225.0%